Why the study?
Do CYP2C9 variant alleles reduce warfarin dose requirements and increase overanticoagulation risk during the induction phase in patients starting warfarin therapy?
Do CYP2C9 variant alleles reduce warfarin dose requirements and increase overanticoagulation risk during the induction phase in patients starting warfarin therapy?
CYP2C9 variant alleles significantly reduce warfarin dose requirements and increase the risk of overanticoagulation as early as the fourth day of treatment.
No takes yet. Share an insight, caveat, or question.
Variants associated with lower doses and early overanticoagulation risk; hypothesis-generating for genotype-guided initiation, needs prospective validation.
Peyvandi et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: